CAPZA Private Debt arranges financing to support Columna Capital’s acquisition of Evidenze Group.

Evidenze Group is a full-service CRO supporting pharmaceutical, biotech and healthcare clients in over 20 countries with complementary services across the clinical development value chain, from early-stage clinical trials through to product commercialisation. Evidenze operates across three core business lines — Clinical Research Services, Scientific Services and Digital Health Services — and serves over 270 active clients, including global pharmaceutical companies, mid-sized biotech firms and non-commercial sponsors.

Since its inception, the Group has experienced strong growth driven by an active buy-and-build strategy, completing multiple acquisitions and expanding its footprint across Spain, Germany, Italy and Portugal; together with organic growth. Today, Evidenze employs more than 450 professionals across Europe.

With the support of Columna Capital, Evidenze aims to accelerate its growth trajectory by further consolidating a fragmented European CRO market, pursuing additional acquisitions and strengthening its service offering, while continuing to invest in talent and operational excellence.

Companies shown herein are for illustrative purposes only as of 07/07/2026 and may no longer be in the portfolio later. This information does not constitute investment research or financial analysis relating to transactions in financial instruments, nor does it constitute an offer to buy or sell any investments, products or services, and should not be considered as solicitation or investment, legal or tax advice, a recommendation for an investment strategy or a personalized recommendation to buy or sell securities.